Opin vísindi

Stabilization and solubilization of difluprednate in aqueous cyclodextrin solution and its characterization for ophthalmic delivery

Show simple item record

dc.contributor Háskóli Íslands
dc.contributor University of Iceland
dc.contributor.author Prajapati, Manisha
dc.contributor.author Loftsson, Thorsteinn
dc.date.accessioned 2022-03-23T13:54:13Z
dc.date.available 2022-03-23T13:54:13Z
dc.date.issued 2022-01
dc.identifier.citation Manisha Prajapati, Thorsteinn Loftsson, Stabilization and solubilization of difluprednate in aqueous cyclodextrin solution and its characterization for ophthalmic delivery, Journal of Drug Delivery Science and Technology, Volume 69, 2022, 103106, ISSN 1773-2247,
dc.identifier.issn 1773-2247
dc.identifier.uri https://hdl.handle.net/20.500.11815/2969
dc.description Publisher´s version / Útgefin grein
dc.description.abstract Difluprednate is a synthetic glucocorticoid used for the treatment of postoperative inflammation and pain associated with endogenous uveitis. It is very lipophilic with limited aqueous solubility and stability. The only available marketed formulation is an oil-in-water ophthalmic emulsion that has many drawbacks. Cyclodextrin (CD) molecules are widely used to increase the solubility and stability of hydrophobic drugs through the for- mation of drug/CD complexes. This study aims to investigate degradation kinetics, stability and solubility of difluprednate in aqueous CD solutions in an effort to develop aqueous eye drop vehicle for ophthalmic delivery. Phase-solubility and kinetics studies were performed in presence of different CDs and polymers. Characterization of the drug/CD complexes was done using techniques like NMR, DSC, and FTIR. The results show that diflu- prednate has maximum stability at pH 5 in aqueous CD solution. HPγCD was found to be the best solubilizer and stabilizer among all the CDs tested. The stability was further improved with the combination of HPγCD and different polymers. Characterization of the difluprednate/HPγCD complex in solid and solution state confirmed the presence of a drug/CD complex. It was possible to solubilize 0.1% difluprednate using HPγCD and stabilize the drug using combination of CD and polymer in aqueous solution
dc.description.sponsorship This work was financially supported by the European Union grant no. MSCA-ITN-2017-765441 (transMed) and the Faculty of Pharmaceutical Sciences, University of Iceland.
dc.format.extent 103106
dc.language.iso en
dc.publisher Elsevier
dc.relation info:eu-repo/grantAgreement/EC/H2020/MSCA-ITN-2017-765441
dc.relation.ispartofseries Journal of Drug Delivery Science and Technology;69
dc.rights info:eu-repo/semantics/openAccess
dc.subject Solubility
dc.subject Stability
dc.subject Cyclodextrins
dc.subject Difluprednate
dc.subject Lyfjaefnafræði
dc.subject Lyfjameðferð
dc.subject Skurðsjúklingar
dc.subject Bólgur
dc.subject.mesh Pharmaceutical chemistry
dc.title Stabilization and solubilization of difluprednate in aqueous cyclodextrin solution and its characterization for ophthalmic delivery
dc.type info:eu-repo/semantics/article
dcterms.license CC BY 4.0 © 2022 The Authors. Published by Elsevier
dc.description.version Peer-Reviewed
dc.identifier.journal Journal of Drug Delivery Science and Technology
dc.identifier.doi 10.1016/j.jddst.2022.103106
dc.contributor.department Lyfjafræðideild (HÍ)
dc.contributor.department Faculty of Pharmaceutical Sciences (UI)
dc.contributor.school Heilbrigðisvísindasvið (HÍ)
dc.contributor.school School of Health Sciences (UI)


Files in this item

This item appears in the following Collection(s)

Show simple item record